35122 Targeting core GC groups: feasibility and impact

Wednesday, June 11, 2014: 10:00 AM
Grand Ballroom A/B/C/D1
Michel Alary, MD, PhD, Population Health and Optimal Health Practices Research Unit, CHU-HSS, Québec, QC, Canada

Will screening certain core risk groups have an impact on the emergence and spread of drug resistant GC? If so, how do we implement the programs?